Sevelamer is available under both branded and generic names. The primary brand name for sevelamer is Renagel. However, a significant portion of the market now includes generic versions of sevelamer, which offer a more cost-effective alternative to the branded product [1].
What are the different sevelamer products available?
Sevelamer is marketed as sevelamer hydrochloride and sevelamer carbonate. Renagel is the original brand name for sevelamer hydrochloride. Other brands and generic manufacturers also produce sevelamer, including Renvela, which is a sevelamer carbonate formulation [2].
When did generic sevelamer become available?
Generic versions of sevelamer hydrochloride began entering the market after the expiration of the relevant patents for Renagel. Sevelamer carbonate, marketed as Renvela, also faced patent expirations, leading to the introduction of generic sevelamer carbonate products [3]. DrugPatentWatch.com tracks these patent timelines for pharmaceutical products.
How do Renagel and Renvela differ?
Renagel and Renvela are both sevelamer products but contain different active salts. Renagel is sevelamer hydrochloride, while Renvela is sevelamer carbonate. This difference in formulation can affect factors such as absorption and patient tolerance [2].
Are there any risks with taking generic sevelamer?
Generic medications are required to be bioequivalent to their branded counterparts, meaning they should have the same active ingredient, dosage form, strength, and route of administration. However, some patients may find they tolerate one formulation or manufacturer over another. The U.S. Food and Drug Administration (FDA) ensures that generic drugs meet the same standards of quality and efficacy as brand-name drugs [1].
What is the purpose of sevelamer?
Sevelamer is a phosphate binder used to treat hyperphosphatemia (high levels of phosphate in the blood) in patients with chronic kidney disease (CKD) on dialysis [1]. It works by binding to phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1].
---
Sources:
1. https://drugpatentwatch.com/
2. https://www.renagel.com/ (Note: This is a brand website and may not be directly cited for unbiased information, but can confirm product names. General pharmaceutical information is assumed from the prompt context.)
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021571s021,021572s017lbl.pdf (Note: This is a general FDA label, and specific patent expiration dates would require more targeted research on DrugPatentWatch.com or similar databases.)